Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Price Target from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned an average recommendation of “Buy” from the ten research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $21.29.

STOK has been the topic of a number of analyst reports. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th.

Insider Activity at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 13,666 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the completion of the transaction, the general counsel now directly owns 21,476 shares in the company, valued at approximately $292,288.36. This trade represents a 38.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the sale, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock worth $809,421 in the last three months. 11.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in STOK. Quest Partners LLC acquired a new stake in Stoke Therapeutics in the second quarter valued at $29,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Stoke Therapeutics during the 2nd quarter worth about $123,000. Intech Investment Management LLC acquired a new position in Stoke Therapeutics in the third quarter valued at approximately $160,000. The Manufacturers Life Insurance Company increased its stake in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after purchasing an additional 1,994 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in Stoke Therapeutics during the third quarter worth approximately $192,000.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $8.96 on Monday. Stoke Therapeutics has a one year low of $4.09 and a one year high of $17.58. The stock has a market cap of $474.58 million, a PE ratio of -4.27 and a beta of 0.95. The stock has a 50 day moving average price of $12.05 and a 200 day moving average price of $13.11.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, analysts predict that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.